Last reviewed · How we verify
NKR-2
At a glance
| Generic name | NKR-2 |
|---|---|
| Also known as | cyclophosphamide 300 mg/m², fludarabine 30 mg/m² |
| Sponsor | Celyad Oncology SA |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer (PHASE1)
- Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer (PHASE1)
- DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 (PHASE1, PHASE2)
- alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (PHASE1)
- Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases (PHASE1)
- EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 (PHASE1)
- A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (PHASE1, PHASE2)
- Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NKR-2 CI brief — competitive landscape report
- NKR-2 updates RSS · CI watch RSS
- Celyad Oncology SA portfolio CI